CDK4/6抑制剂阿贝西利联合顺铂对人胃癌细胞生物学行为的影响

doi:10.3969/j.issn.1004-616x.2024.05.008

癌变·畸变·突变 ›› 2024, Vol. 36 ›› Issue (5): 384-390.doi: 10.3969/j.issn.1004-616x.2024.05.008

• 论著 • 上一篇

CDK4/6抑制剂阿贝西利联合顺铂对人胃癌细胞生物学行为的影响

邸荣炜¹, 付鑫雅¹, 马秀梅^1,2, 李超³, 海玲^1,2

1. 内蒙古医科大学基础医学院病理教研室, 内蒙古呼和浩特 010059;
2. 内蒙古医科大学附属医院病理科, 内蒙古呼和浩特 010059;
3. 内蒙古医科大学附属医院肿瘤内科, 内蒙古呼和浩特 010059

收稿日期:2023-12-01 修回日期:2024-02-23 发布日期:2024-10-15
通讯作者: 马秀梅
作者简介:邸荣炜,E-mail:920239964@qq.com。

Effects of CDK4/6 inhibitor abemaciclib and cisplatin on biological behavior of human gastric cancer cells

DI Rongwei¹, FU Xinya¹, MA Xiumei^1,2, LI Chao³, HAI Ling^1,2

1. Department of Pathology, School of Basic Medical Sciences of Inner Mongolia Medical College, Hohhot 010059;
2. Department of Pathology, The Affiliated Hospital of Inner Mongolia Medical College, Hohhot 010059;
3. Department of Medical Oncology, The Affiliated Hospital of Inner Mongolia Medical College, Hohhot 010059, Inner Mongolia, China

Received:2023-12-01 Revised:2024-02-23 Published:2024-10-15

摘要/Abstract

摘要： 目的： 探讨CDK4和CDK6(CDK4/6)抑制剂阿贝西利与顺铂联合作用对人胃癌细胞生物学行为的影响。方法： 利用生物信息学网站UALCAN在线分析TCGA数据库，获取人胃癌组织与正常胃组织中CDK4/6基因表达情况；培养人胃癌细胞SGC-7901，采用Western blot检测细胞中CDK4/6蛋白的表达。利用细胞增殖实验检测顺铂和阿贝西利单独作用24 h的半数抑制浓度，然后将细胞分为空白对照组、0.5 μg/mL顺铂组、10 μmol/L阿贝西利组、10 μmol/L阿贝西利和0.5 μg/mL顺铂联合组，分别作用24、48、72 h后采用CCK-8法、流式细胞术、划痕实验、Transwell实验检测各组中SGC-7901细胞的增殖、凋亡、迁移和侵袭情况。结果： 生物信息学分析表明CDK4/6蛋白在人胃癌组织中的表达显著高于正常胃组织(P<0.05)。Western blot实验显示，与对照组相比，人胃癌细胞SGC-7901中CDK4/6蛋白的表达水平均显著升高(P<0.05)。CCK-8实验结果显示最接近IC₅₀值的顺铂浓度为0.5 μg/mL，阿贝西利浓度为10 μmol/L，故后续选择此浓度进行试验。与空白对照组、顺铂组、阿贝西利单独组相比，阿贝西利联合顺铂组的细胞增殖抑制率明显增强且具有时间依赖性(r=0.949，P<0.01)，细胞凋亡率亦显著升高(P<0.01)，迁移和侵袭能力均显著减弱(P<0.01)。结论： CDK4/6在人胃癌组织和细胞中的表达均显著升高，CDK4/6抑制剂阿贝西利联合顺铂显示出协同作用，可显著抑制人胃癌细胞的增殖、迁移和侵袭，并促进其凋亡。

关键词: CDK4/6, 胃癌, 阿贝西利, 顺铂, 生物学行为

Abstract: OBJECTIVE： To investigate biological behavior of human gastric cancer cells after their treatment with the CDK4 and CDK6 (CDK4/6) inhibitor abemaciclib，and cisplatin. METHODS： The TCGA database resources and the bioinformatics UALCAN website were used to obtain the expression of CDK4/6 genes in gastric cancers and normal gastric tissues. Western blot test was used to detect expression of CDK4 and CDK6 albumen in the stomach-carcinoma cell line SGC7901 and the regular gastric mucous membrane cell line GES-1. The CCK-8 method was used to screen for the optimal cell growth inhibition concentration. The cells were divided into several groups：blank control，0.5 μg/mL cisplatin，10 μmol/L abemaciclib+0.5 μg/mL cisplatin，and 10 μmol/L abemaciclib groups. These groups were treated for 24，48 and 72 h. Then CCK-8 method，flow cytometry，scratch assay and Transwell assay were used to detect the proliferation，apoptosis，migration and invasion gastric cancer cells SGC-7901 in each subgroup RESULTS： Based on bioinformatics analysis， expression of CDK4/6 proteins in human gastric cancer tissues was significantly higher than that in normal gastric tissues (P<0.05). Western blot analyses showed that expression of CDK4/6 proteins was significantly increased in SGC7901 compared with that in normal tissues (P<0.05). According to the CCK-8 results，the cisplatin concentration for the IC₅₀ value was 0.5 μg/mL and the abemaciclib was 10 μmol/L，therefore these concentrations were used for subsequent experiments. Compared with the blank control group，the combined treatment inhibited cell proliferation significantly (P<0.01)，and the inhibition ability was time-dependent(r=0.949，P<0.01). The level of apoptosis was significantly increased (P<0.01)，and both migration and invasion capacity were significantly reduced (P<0.01). CONCLUSION： Expression of CDK4/6 was significantly increased in human gastric cancer tissues and cells. Combined treatment of these cells with abemaciclib and cisplatin showed synergistic effects，which significantly inhibited the proliferation，migration，invasion of human gastric cancer cells and promoted apoptosis.

Key words: CDK4/6, gastric cancer, abemaciclib, cisplatin, biological behavior

中图分类号:

R735.2

邸荣炜, 付鑫雅, 马秀梅, 李超, 海玲. CDK4/6抑制剂阿贝西利联合顺铂对人胃癌细胞生物学行为的影响[J]. 癌变·畸变·突变, 2024, 36(5): 384-390.

DI Rongwei, FU Xinya, MA Xiumei, LI Chao, HAI Ling. Effects of CDK4/6 inhibitor abemaciclib and cisplatin on biological behavior of human gastric cancer cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(5): 384-390.

参考文献

[1] QI J L, LI M L, WANG L J, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8(12): 943-955.
[2] FASSL A, GENG Y, SICINSKI P. CDK4 and CDK6 kinases: from basic science to cancer therapy[J]. Science, 2022, 375(6577): eabc1495.
[3] ADON T, SHANMUGARAJAN D, KUMAR H Y. CDK4/6 inhibitors: a brief overview and prospective research directions[J]. RSC Adv, 2021, 11(47): 29227-29246.
[4] GAO X L, LEONE G W, WANG H Z. Cyclin D-CDK4/6 functions in cancer[J]. Adv Cancer Res, 2020, 148: 147-169.
[5] SHERR C J, BEACH D, SHAPIRO G I. Targeting CDK4 and CDK6: from discovery to therapy[J]. Cancer Discov, 2016, 6(4): 353-367.
[6] NEBENFUEHR S, KOLLMANN K, SEXL V. The role of CDK6 in cancer[J]. Int J Cancer, 2020, 147(11): 2988-2995.
[7] VIJAYARAGHAVAN S, MOULDER S, KEYOMARSI K, et al. Inhibiting CDK in cancer therapy: current evidence and future directions[J]. Target Oncol, 2018, 13(1): 21-38.
[8] KLEIN M E, KOVATCHEVA M, DAVIS L E, et al. CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought[J]. Cancer Cell, 2018, 34(1): 9-20.
[9] VERMEULEN K, VAN BOCKSTAELE D R, BERNEMAN Z N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer[J]. Cell Prolif, 2003, 36(3): 131-149.
[10] GOEL S, DECRISTO M J, WATT A C, et al. CDK4/6 inhibition triggers anti-tumour immunity[J]. Nature, 2017, 548(7668): 471-475.
[11] SLEDGE G W Jr, TOI M, NEVEN P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR⁺/HER²^- advanced breast cancer who had progressed while receiving endocrine therapy[J]. J Clin Oncol, 2017, 35(25): 2875-2884.
[12] BRAAL C L, JONGBLOED E M, WILTING S M, et al. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences[J]. Drugs, 2021, 81(3): 317-331.
[13] HAMILTON E, CORTES J, OZYILKAN O, et al. nextMONARCH: abemaciclib monotherapy or combined with tamoxifen for metastatic breast cancer[J]. Clin Breast Cancer, 2021, 21(3): 181-190.e2.
[14] JOHNSTON S R D, HARBECK N, HEGG R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR⁺, HER²^-, node-positive, high-risk, early breast cancer (monarchE)[J]. J Clin Oncol, 2020, 38(34): 3987-3998.
[15] DHIR T, SCHULTZ C W, JAIN A, et al. Abemaciclib is effective against pancreatic cancer cells and synergizes with HuR and YAP1 inhibition[J]. Mol Cancer Res, 2019, 17(10): 2029-2041.
[16] LIU Y, ZHAO R S, FANG S S, et al. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways[J]. Fundam Clin Pharmacol, 2021, 35(1): 156-164.
[17] O’LEARY B, FINN R S, TURNER N C. Treating cancer with selective CDK4/6 inhibitors[J]. Nat Rev Clin Oncol, 2016, 13(7): 417-430.
[18] GOEL S, BERGHOLZ J S, ZHAO J J. Targeting CDK4 and CDK6 in cancer[J]. Nat Rev Cancer, 2022, 22(6): 356-372.
[19] DIGIACOMO G, FUMAROLA C, LA MONICA S, et al. CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells[J]. Front Oncol, 2022, 12: 942341.
[20] 郭晶晶, 牟迪, 于文文, 等. Abemaciclib抑制c-Myc高表达小细胞肺癌增殖、侵袭和迁移的生物学功能的研究[J]. 中国肺癌杂志, 2023, 26(2): 105-112.

CDK4/6抑制剂阿贝西利联合顺铂对人胃癌细胞生物学行为的影响

Effects of CDK4/6 inhibitor abemaciclib and cisplatin on biological behavior of human gastric cancer cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄丛改, 刘清, 郑树涛, 刘涛, 谭依依, 彭天元, 陈娇, 卢晓梅. CXCR2在食管癌组织中的表达及其对食管癌细胞生物学行为的影响[J]. 癌变·畸变·突变, 2024, 36(1): 53-57,65.
[2]	王馨焱, 刘晓玲, 贾军梅. 淋巴细胞亚群在胃癌免疫检查点抑制剂治疗中的研究进展[J]. 癌变·畸变·突变, 2024, 36(1): 80-83.
[3]	何广思, 魏洁, 张健. 血清miRNA-183与CA199联合检测在胃癌诊断和预后评估中的价值[J]. 癌变·畸变·突变, 2023, 35(6): 457-461,466.
[4]	秦景娜, 周英发, 刘贺勇. 炎症指标和肿瘤标记物联合检测对术前胃癌分期的诊断价值[J]. 癌变·畸变·突变, 2023, 35(2): 139-143.
[5]	许浩, 胡碧川, 邹伟, 段雅斌. 行根治术的Ⅲ期胃癌患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(1): 30-36.
[6]	齐建考, 汤肖, 孙世辉, 寇艳方, 崔志勤. 复方皂刺汤对顺铂联合吉西他滨抑制非小细胞肺癌生长的作用及其机制研究[J]. 癌变·畸变·突变, 2022, 34(5): 366-372,403.
[7]	张晓帆, 钟旋, 罗杰鹏, 欧阳斌发, 李博, 李华文, 彭晓琳. 深圳市南山区2011—2019年胃癌发病特征及趋势[J]. 癌变·畸变·突变, 2022, 34(4): 269-272,278.
[8]	余悦华, 梁桓熙, 辛雨濛, 孙震晓. 甘草干姜汤的抗胃癌作用及其机制研究[J]. 癌变·畸变·突变, 2022, 34(3): 219-226.
[9]	杨婵君, 陈雯恬, 刘静. 胶原蛋白作为胃癌潜在生物标志物的生物信息学分析[J]. 癌变·畸变·突变, 2021, 33(6): 410-419.
[10]	崔昭阳, 李素娜, 姜旭倩, 王弈丹, 侯丽颖. 芹菜素激活TRAIL死亡受体参与诱导胃癌SGC-7901细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(1): 32-36.
[11]	刘鹏, 白意晓. miR-29a对人胃癌细胞增殖、迁移的影响及其机制研究[J]. 癌变·畸变·突变, 2020, 32(6): 452-456,463.
[12]	吕燕萍, 吴传城, 杨双凤, 何陈周, 韩仁杰, 颜伟, 刘宝英. 胃癌差异表达miRNA及其相关基因的单核苷酸多态性与胃癌预后的相关性研究[J]. 癌变·畸变·突变, 2020, 32(5): 380-386.
[13]	王耀杰, 相晓晗, 韩丽娜, 李军, 霍炳杰, 赵连梅. 中药地锦草乙醇提取物体外抑制胃癌细胞增殖活性及机制研究[J]. 癌变·畸变·突变, 2020, 32(3): 187-193.
[14]	李丹, 刘宝英, 余明明, 庄海林, 揭金花, 吴涵梅. NFKBIA基因多态性、饮食习惯及其交互作用与胃癌易感性的关系[J]. 癌变·畸变·突变, 2020, 32(3): 198-202.
[15]	申志华, 黄萨础拉, 马秀梅. 乙酰肝素酶、E-cadherin、N-cadherin和vimentin蛋白在胃癌中的表达及其意义[J]. 癌变·畸变·突变, 2020, 32(2): 98-104.